NewAmsterdam Pharma Co. NV (NAMS)
27.32
+0.46
(+1.73%)
USD |
NASDAQ |
Aug 25, 16:00
27.34
+0.02
(+0.09%)
After-Hours: 19:30
NewAmsterdam Pharma Enterprise Value : 2.524B for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 2.524B |
| August 21, 2026 | 2.644B |
| August 20, 2026 | 2.633B |
| August 19, 2026 | 2.721B |
| August 18, 2026 | 2.571B |
| August 17, 2026 | 2.530B |
| August 14, 2026 | 2.539B |
| August 13, 2026 | 2.503B |
| August 12, 2026 | 2.639B |
| August 11, 2026 | 2.614B |
| August 10, 2026 | 2.657B |
| August 07, 2026 | 2.654B |
| August 06, 2026 | 2.620B |
| August 05, 2026 | 2.591B |
| August 04, 2026 | 2.606B |
| August 03, 2026 | 2.599B |
| July 31, 2026 | 2.634B |
| July 30, 2026 | 2.713B |
| July 29, 2026 | 2.649B |
| July 28, 2026 | 2.657B |
| July 27, 2026 | 2.920B |
| July 24, 2026 | 2.852B |
| July 23, 2026 | 2.959B |
| July 22, 2026 | 3.094B |
| July 21, 2026 | 3.170B |
| Date | Value |
|---|---|
| July 20, 2026 | 2.856B |
| July 17, 2026 | 3.092B |
| July 16, 2026 | 3.018B |
| July 15, 2026 | 3.127B |
| July 14, 2026 | 3.281B |
| July 13, 2026 | 3.280B |
| July 10, 2026 | 3.513B |
| July 09, 2026 | 3.591B |
| July 08, 2026 | 3.580B |
| July 07, 2026 | 3.717B |
| July 06, 2026 | 3.471B |
| July 02, 2026 | 3.463B |
| July 01, 2026 | 3.503B |
| June 30, 2026 | 3.352B |
| June 29, 2026 | 3.313B |
| June 26, 2026 | 3.240B |
| June 25, 2026 | 3.064B |
| June 24, 2026 | 3.169B |
| June 23, 2026 | 3.025B |
| June 22, 2026 | 2.957B |
| June 18, 2026 | 2.842B |
| June 17, 2026 | 2.879B |
| June 16, 2026 | 2.884B |
| June 15, 2026 | 2.932B |
| June 12, 2026 | 2.908B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ProQR Therapeutics NV | 224.10M |
| Pharming Group NV | 779.59M |
| argenx SE | 62.50B |
| Arcutis Biotherapeutics, Inc. | 2.987B |
| Damora Therapeutics, Inc. | 1.461B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -64.14M |
| Revenue (Quarterly) | 3.701M |
| Total Expenses (Quarterly) | 67.84M |
| EPS Diluted (Quarterly) | -0.5199 |
| Gross Profit Margin (Quarterly) | 98.41% |
| Profit Margin (Quarterly) | -1.73K% |
| Earnings Yield | -7.97% |
| Normalized Earnings Yield | -7.148 |